氟伐他汀对充血性心力衰竭患者血清sICAM-1和sVCAM-1的影响

目的:探讨氟伐他汀短期治疗对充血性心力衰竭(CHF)患者血清中可溶性细胞间黏附分子-1(sICAM-1)、可溶性血管细胞黏附分子-1(sVCAM-1)和肿瘤坏死因子α(TNF-α)水平的影响。方法:将97例CHF患者随机分为对照组(常规治疗组)和试药组(氟伐他汀组)。采用ELISA测定治疗前及治疗两周后血清中sICAM-1、sVCAM-1和TNF-α水平。结果:两种方法都可以明显降低血清sICAM-1、sVCAM-1和TNF-α水平(P0.05);试药组血清TNF-α水平降低更为显著(P0.05),但血清sICAM-1和sVCAM-1降低水平与对照组无显著差别。结论:在常规治疗基础上短期加用氟伐他汀治疗不能进一步降低CHF患者血清sICAM-1和sVCAM-1水平。

Effects of fluvastatin on serum sICAM-1 and sVCAM-1 in patients with congestive heart failure

AIM: To observe the effects of short-term treatment of fluvastatin on serum soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1) and tumor necrosis factor-α (TNF-α) in patients with congestive heart failure (CHF). METHODS: Ninety seven patients with CHF were randomly divided into control group (conventional treatment group) and test drug group (fluvastatin group). Levels of serum sICAM-1, sVCAM-1 and TNF-α were measured using enzyme-linked immunosorbent assay (ELISA) before treatment and after 2 weeks of treatment. RESULTS: Both methods can significantly reduce serum sICAM-1, sVCAM-1 and TNF-α level (P<0.05). TNF-α levels of test drug groups reduced more significantly (P<0.05), whereas decreased levels of serum sICAM-1 and sVCAM-1 had no significant difference compared with control group. CONCLUSION: On the basis of conventional treatment together with short-term fluvastatin treatment, no further reduction of the levels of sICAM-1 and sVCAM-1 were demonstrated.